Mesenchymal stem cell-derived cell-free technologies: a patent landscape.
Biotechnol Lett
; 46(5): 907-924, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-38900338
ABSTRACT
Mesenchymal stem/stromal cells (MSC) play a pivotal role in regenerative therapies. Recent studies show that factors secreted by MSC can replicate their biological activity, driving the emergence of cell-free therapy, likely to surpass stem cell therapy. Patents are an objective measure of R&D and innovation activities, and patent mapping allows us to verify the state of the art and technology, anticipate trends, and identify emerging lines of research. This review performed a search on Derwent World Patents Index™ and retrieved 269 patent families related to the MSC-derived cell-free products. Analysis reveals an exponential increase in patents from the mid-2010s, primarily focusing on exosomes. The patent's contents offer a great diversity of applications and associated technologies by using the products as medicinal agents or drug delivery systems. Nevertheless, numerous application branches remain unexplored, suggesting vast potential for cell-free technologies alone or combined with other approaches.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Patents as Topic
/
Mesenchymal Stem Cells
Limits:
Animals
/
Humans
Language:
En
Journal:
Biotechnol Lett
/
Biotechnol. lett
/
Biotechnology letters
Year:
2024
Document type:
Article
Affiliation country:
Brazil
Country of publication:
Netherlands